N
Neil Rabin
Researcher at University College London Hospitals NHS Foundation Trust
Publications - 106
Citations - 2187
Neil Rabin is an academic researcher from University College London Hospitals NHS Foundation Trust. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 15, co-authored 84 publications receiving 1693 citations. Previous affiliations of Neil Rabin include University College London & University College Hospital.
Papers
More filters
Journal ArticleDOI
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos,Albert Oriol,Hareth Nahi,Jesús F. San-Miguel,Nizar J. Bahlis,Saad Z. Usmani,Neil Rabin,Robert Z. Orlowski,Mieczysław Komarnicki,Kenshi Suzuki,Torben Plesner,Sung-Soo Yoon,Dina Ben Yehuda,Paul G. Richardson,Hartmut Goldschmidt,Hartmut Goldschmidt,Donna E. Reece,Steen Lisby,Nushmia Z. Khokhar,Lisa O'Rourke,Christopher Chiu,Xiang Qin,Mary E. Guckert,Tahamtan Ahmadi,Philippe Moreau +24 more
TL;DR: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model
TL;DR: Tissue homing of systemically administered mesenchymal stem cells is influenced by host factors such as age, is diminished by prolonged in vitro culture, and can be increased by enforced expression of CXCR4, at least in irradiated hosts.
Journal ArticleDOI
Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy.
Gordon Cook,A John Ashcroft,Guy Pratt,Rakesh Popat,Karthik Ramasamy,Martin Kaiser,Matthew W Jenner,Sarah Henshaw,Rachel Hall,Jonathan Sive,S. A. Stern,Matthew Streetly,Ceri Bygrave,Richard Soutar,Neil Rabin,Graham H. Jackson +15 more
TL;DR: The UK index case was identified on the 31st of January, 2020 and given the rapid spread and high mortality rate of COVID‐19, it is imperative to define the impact on patients with co‐existing medical conditions.
Journal ArticleDOI
Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction.
Arash Latifoltojar,Margaret A Hall-Craggs,Margaret A Hall-Craggs,Alan Bainbridge,Neil Rabin,Rakesh Popat,Ali Rismani,Shirley D'Sa,Nikolaos Dikaios,Magdalena Sokolska,Michela Antonelli,Sebastien Ourselin,Kwee Yong,Stuart A. Taylor,Stuart A. Taylor,Steve Halligan,Steve Halligan,Shonit Punwani,Shonit Punwani +18 more
TL;DR: WB-MRI derived focal lesion sFF shows promise as an imaging biomarker of treatment response in newly diagnosed MM and fat fraction and ADC significantly increase in myeloma lesions responding to treatment.
Journal ArticleDOI
Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response
Arash Latifoltojar,Margaret A Hall-Craggs,Neil Rabin,Rakesh Popat,Alan Bainbridge,Nikolaos Dikaios,Magdalena Sokolska,Ali Rismani,Shirley D'Sa,Shonit Punwani,Kwee Yong +10 more
TL;DR: It is concluded that early lesional sFF changes may provide important information on depth of response, and are worthy of further prospective study.